FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 344:1358-1365 May 3, 2001 Number 18 Next

	Full Text PDF Editorial by Schwartz, R. S. Editorial by Wood, A. J.J. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background The benefits of angiotensin-converting–enzyme inhibitors and beta-blockers may be smaller in black patients than in patients of other races, but it is unknown whether race influences the response to carvedilol in patients with chronic heart failure.

Methods In the U.S. Carvedilol Heart Failure Trials Program, 217 black and 877 nonblack patients (in New York Heart Association class II, III, or IV and with a left ventricular ejection fraction of no more than 0.35) were randomly assigned to receive placebo or carvedilol (at doses of 6.25 to 50 mg twice daily) for up to 15 months. The effects of carvedilol on ejection fraction, clinical status, and major clinical events were retrospectively compared between black and nonblack patients.

Results As compared with placebo, carvedilol lowered the risk of death from any cause or hospitalization for any reason by 48 percent in black patients and by 30 percent in nonblack patients. Carvedilol reduced the risk of worsening heart failure (heart failure leading to death, hospitalization, or a sustained increase in medication) by 54 percent in black patients and by 51 percent in nonblack patients. The ratios of the relative risks associated with carvedilol for these two outcome variables in black as compared with nonblack patients were 0.74 (95 percent confidence interval, 0.42 to 1.34) and 0.94 (95 percent confidence interval, 0.43 to 2.05), respectively. Carvedilol also improved functional class, ejection fraction, and the patients' and physicians' global assessments in both the black patients and the nonblack patients. For all these measures of outcome and clinical status, carvedilol was superior to placebo within each racial cohort (P<0.05 in all analyses), and there was no significant interaction between race and treatment (P> 0.05 in all analyses).

Conclusions The benefit of carvedilol was apparent and of similar magnitude in both black and nonblack patients with heart failure.

Source Information

From the University of Texas Southwestern Medical Center, Dallas (C.W.Y.); Stanford University School of Medicine, Palo Alto, Calif. (M.B.F.); Boston University School of Medicine, Boston (W.S.C.); the University of Utah School of Medicine, Salt Lake City (E.M.G.); the University of Colorado School of Medicine, Denver (M.R.B.); the University of Minnesota Medical School, Minneapolis (J.N.C.); Glaxo SmithKline, King of Prussia, Pa. (M.A.L., S.T.Y.); and Columbia University College of Physicians and Surgeons, New York (M.P.).

Address reprint requests to Dr. Yancy at the Division of Cardiology, CS7 102, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390-9047, or at clyde.yancy{at}utsouthwestern.edu.

Full Text of this Article

This article has been cited by other articles:

• Anderson, W. (2008). Teaching `Race' at Medical School: Social Scientists on the Margin. Social Studies of Science 38: 785-800 [Abstract]  
• Johnson, J. A. (2008). Ethnic Differences in Cardiovascular Drug Response: Potential Contribution of Pharmacogenetics. Circulation 118: 1383-1393 [Full Text]  
• Linas, S. L. (2008). Are Two Better Than One? Angiotensin-Converting Enzyme Inhibitors Plus Angiotensin Receptor Blockers for Reducing Blood Pressure and Proteinuria in Kidney Disease. CJASN 3: S17-S23 [Abstract] [Full Text]  
• Davis, A. M., Vinci, L. M., Okwuosa, T. M., Chase, A. R., Huang, E. S. (2007). Cardiovascular Health Disparities: A Systematic Review of Health Care Interventions. Med Care Res Rev 64: 29S-100S [Abstract]  
• Barr, D. A. (2005). The Practitioner's Dilemma: Can We Use a Patient's Race To Predict Genetics, Ancestry, and the Expected Outcomes of Treatment?. ANN INTERN MED 143: 809-815 [Abstract] [Full Text]  
• Taylor, A. L., Wright, J. T. Jr, Cooper, R. S., Psaty, B. M., Taylor, A. L., Wright, J. T. Jr, Cooper, R. S., Psaty, B. M. (2005). Importance of Race/Ethnicity in Clinical Trials: Lessons From the African-American Heart Failure Trial (A-HeFT), the African-American Study of Kidney Disease and Hypertension (AASK), and the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Circulation 112: 3654-3666 [Full Text]  
• Smith, G. L., Shlipak, M. G., Havranek, E. P., Masoudi, F. A., McClellan, W. M., Foody, J. M., Rathore, S. S., Krumholz, H. M. (2005). Race and Renal Impairment in Heart Failure: Mortality in Blacks Versus Whites. Circulation 111: 1270-1277 [Abstract] [Full Text]  
• Yancy, C. W., Benjamin, E. J., Fabunmi, R. P., Bonow, R. O. (2005). Discovering the Full Spectrum of Cardiovascular Disease: Minority Health Summit 2003: Executive Summary. Circulation 111: 1339-1349 [Full Text]  
• Benjamin, I. J., Arnett, D. K., Loscalzo, J. (2005). Discovering the Full Spectrum of Cardiovascular Disease: Minority Health Summit 2003: Report of the Basic Science Writing Group. Circulation 111: e120-e123 [Full Text]  
• Moran, A. E., Cooper, R. S., Fitzgibbons, T. P., Chow, A. Y., Bellin, E. Y., Eisenberger, A. B., Taylor, A. L., Cohn, J., Worcel, M. (2005). Isosorbide dinitrate and hydralazine in blacks with heart failure.. NEJM 352: 1041-1043 [Full Text]  
• Taylor, A. L., Ziesche, S., Yancy, C., Carson, P., D'Agostino, R. Jr., Ferdinand, K., Taylor, M., Adams, K., Sabolinski, M., Worcel, M., Cohn, J. N., the African-American Heart Failure Trial Investiga, (2004). Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure. NEJM 351: 2049-2057 [Abstract] [Full Text]  
• Moreno-John, G., Gachie, A., Fleming, C. M., NApoles-Springer, A., Mutran, E., Manson, S. M., PErez-Stable, E. J. (2004). Ethnic Minority Older Adults Participating in Clinical Research: Developing Trust. J Aging Health 16: 93S-123S [Abstract]  
• Satwani, S., Dec, G. W., Narula, J. (2004). {beta}-Adrenergic Blockers in Heart Failure: Review of Mechanisms of Action and Clinical Outcomes. J CARDIOVASC PHARMACOL THER 9: 243-255 [Abstract]  
• Sankar, P., Cho, M. K., Condit, C. M., Hunt, L. M., Koenig, B., Marshall, P., Lee, S. S.-J., Spicer, P. (2004). Genetic Research and Health Disparities. JAMA 291: 2985-2989 [Abstract] [Full Text]  
• Julius, S., Alderman, M. H., Beevers, G., Dahlof, B., Devereux, R. B., Douglas, J. G., Edelman, J. M., Harris, K. E., Kjeldsen, S. E., Nesbitt, S., Randall, O. S., Wright, J. T. Jr (2004). Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: The life study. J Am Coll Cardiol 43: 1047-1055 [Abstract] [Full Text]  
• Sackner-Bernstein, J. D., Skopicki, H. A. (2004). Racing away from bias. J Am Coll Cardiol 43: 785-786 [Full Text]  
• de Denus, S., Pharand, C., Williamson, D. R. (2004). Brain Natriuretic Peptide in the Management of Heart Failure: The Versatile Neurohormone. Chest 125: 652-668 [Abstract] [Full Text]  
• Feldman, A. M. (2003). The emerging role of pharmacogenomics in the treatment of patients with heart failure. Ann. Thorac. Surg. 76: S2246-2253 [Full Text]  
• Yang, S.-P., Ho, L.-J., Lin, Y.-L., Cheng, S.-M., Tsao, T.-P., Chang, D.-M., Hsu, Y.-L., Shih, C.-Y., Juan, T.-Y., Lai, J.-H. (2003). Carvedilol, a new antioxidative {beta}-blocker, blocks in vitro human peripheral blood T cell activation by downregulating NF-{kappa}B activity. Cardiovasc Res 59: 776-787 [Abstract] [Full Text]  
• Rathore, S. S., Foody, J. M., Wang, Y., Smith, G. L., Herrin, J., Masoudi, F. A., Wolfe, P., Havranek, E. P., Ordin, D. L., Krumholz, H. M. (2003). Race, Quality of Care, and Outcomes of Elderly Patients Hospitalized With Heart Failure. JAMA 289: 2517-2524 [Abstract] [Full Text]  
• Shekelle, P. G., Rich, M. W., Morton, S. C., Atkinson, Col. S. W., Tu, W., Maglione, M., Rhodes, S., Barrett, M., Fonarow, G. C., Greenberg, B., Heidenreich, P. A., Knabel, T., Konstam, M. A., Steimle, A., Warner Stevenson, L. (2003). Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: A meta-analysis of major clinical trials. J Am Coll Cardiol 41: 1529-1538 [Abstract] [Full Text]  
• Tangeman, H. J, Patterson, J H. (2003). Extended-Release Metoprolol Succinate in Chronic Heart Failure. The Annals of Pharmacotherapy 37: 701-710 [Abstract] [Full Text]  
• Ben-Yehuda, O. (2003). Hypertension, angiotensin II, aldosterone, and race. J Am Coll Cardiol 41: 1156-1158 [Full Text]  
• Bonds, D. E., Zaccaro, D. J., Karter, A. J., Selby, J. V., Saad, M., Goff, D. C. Jr (2003). Ethnic and Racial Differences in Diabetes Care: The Insulin Resistance Atherosclerosis Study. Diabetes Care 26: 1040-1046 [Abstract] [Full Text]  
• Gheorghiade, M., Colucci, W. S., Swedberg, K. (2003). {beta}-Blockers in Chronic Heart Failure. Circulation 107: 1570-1575 [Full Text]  
• Douglas, J. G., Bakris, G. L., Epstein, M., Ferdinand, K. C., Ferrario, C., Flack, J. M., Jamerson, K. A., Jones, W. E., Haywood, J., Maxey, R., Ofili, E. O., Saunders, E., Schiffrin, E. L., Sica, D. A., Sowers, J. R., Vidt, D. G., the Hypertension in African Americans Working Grou, (2003). Management of High Blood Pressure in African Americans: Consensus Statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med 163: 525-541 [Full Text]  
• Chassot, P.-G., Delabays, A., Spahn, D. R. (2002). Preoperative evaluation of patients with, or at risk of, coronary artery disease undergoing non-cardiac surgery. Br J Anaesth 89: 747-759 [Abstract] [Full Text]  
• Benjamin, E. J., Smith, S. C. Jr, Cooper, R. S., Hill, M. N., Luepker, R. V. (2002). Task Force #1--magnitude of the prevention problem: opportunities and challenges. J Am Coll Cardiol 40: 588-603 [Full Text]  
• DeMets, D. L., Califf, R. M. (2002). Lessons Learned From Recent Cardiovascular Clinical Trials: Part I. Circulation 106: 746-751 [Full Text]  
• Gheorghiade, M., Goldstein, S. (2002). {beta}-Blockers in the Post-Myocardial Infarction Patient. Circulation 106: 394-398 [Full Text]  
• Dries, D. L., Strong, M. H., Cooper, R. S., Drazner, M. H. (2002). Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients. J Am Coll Cardiol 40: 311-317 [Abstract] [Full Text]  
• Kennedy, H. L., Rosenson, R. S. (2002). Physicians' interpretation of "class effects": A need for thoughtful re-evaluation. J Am Coll Cardiol 40: 19-26 [Abstract] [Full Text]  
• Andreka, P., Aiyar, N., Olson, L. C., Wei, J. Q., Turner, M. S., Webster, K. A., Ohlstein, E. H., Bishopric, N. H. (2002). Bucindolol Displays Intrinsic Sympathomimetic Activity in Human Myocardium. Circulation 105: 2429-2434 [Abstract] [Full Text]  
• McMurray, J., Pfeffer, M. A. (2002). New Therapeutic Options in Congestive Heart Failure: Part II. Circulation 105: 2223-2228 [Full Text]  
• Bundkirchen, A., Brixius, K., Bolck, B., Schwinger, R. H. G. (2002). Bucindolol Exerts Agonistic Activity on the Propranolol-Insensitive State of beta 1-Adrenoceptors in Human Myocardium. J. Pharmacol. Exp. Ther. 300: 794-801 [Abstract] [Full Text]  
• Farrell, M. H., Foody, J. M., Krumholz, H. M. (2002). {beta}-Blockers in Heart Failure: Clinical Applications. JAMA 287: 890-897 [Abstract] [Full Text]  
• McNeil, B. J. (2001). Hidden Barriers to Improvement in the Quality of Care. NEJM 345: 1612-1620 [Full Text]  
• Bovet, P., Paccaud, F., McLeod, H. L., Masoudi, F. A., Havranek, E. P., Ofili, E., Flack, J., Gibbons, G., Exner, D. V., Domanski, M. J., Cohn, J. N., Schwartz, R. S. (2001). Race and Responsiveness to Drugs for Heart Failure. NEJM 345: 766-768 [Full Text]  
• (2001). Race and Response to Therapies. Journal Watch Cardiology 2001: 2-2 [Full Text]  
• Braunwald, E. (2001). Expanding Indications for Beta-Blockers in Heart Failure. NEJM 344: 1711-1712 [Full Text]  
• (2001). Racial Differences in Response to Heart Failure Therapy?. JWatch General 2001: 1-1 [Full Text]  
• Schwartz, R. S. (2001). Racial Profiling in Medical Research. NEJM 344: 1392-1393 [Full Text]  
• Wood, A. J.J. (2001). Racial Differences in the Response to Drugs -- Pointers to Genetic Differences. NEJM 344: 1393-1396 [Full Text]